{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:00:19Z","timestamp":1791608419726,"version":"4.3.4"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,3,15]],"date-time":"2004-03-15T00:00:00Z","timestamp":1079308800000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:p><jats:bold>Background and Objectives\u2002<\/jats:bold> Patients suffering from von Willebrand disease who are not responsive to desmopressin require substitutive treatment. This study was part of the development of a second\u2010generation plasma\u2010derived von Willebrand factor (VWF) concentrate, the manufacturing process of which includes two complementary viral\u2010inactivation\/elimination steps that are effective against non\u2010enveloped viruses.<\/jats:p><jats:p><jats:bold>Materials and Methods\u2002<\/jats:bold> VWF was purified from solvent\/detergent\u2010treated cryoprecipitate through a combination of anion\u2010exchange and affinity chromatography. The VWF preparation was diluted and filtered through filters with pore size of 35\u00a0nm. After concentration and formulation, the product was freeze\u2010dried and further heated at 80\u00a0\u00b0C for 72\u00a0h. Tests were performed to evaluate the effects of nanofiltration and dry heating on VWF multimeric structure and function.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Nanofiltration and dry heating of the formulated product increased viral safety but did not modify VWF multimeric structure. Furthermore, these steps did not alter the ability of VWF to bind to platelet glycoprotein Ib, collagen and Factor VIII.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> We have perfected a large\u2010scale manufacturing process to produce a human plasma\u2010derived VWF concentrate that boasts high specific activity and is very safe for the treatment of patients with von Willebrand disease.<\/jats:p>","DOI":"10.1111\/j.0042-9007.2004.00398.x","type":"journal-article","created":{"date-parts":[[2004,3,15]],"date-time":"2004-03-15T16:06:55Z","timestamp":1079366815000},"page":"100-104","source":"Crossref","is-referenced-by-count":23,"title":["<i>In vitro<\/i> study of a triple\u2010secured von Willebrand factor concentrate"],"prefix":"10.1111","volume":"86","author":[{"given":"C.","family":"Mazurier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Poulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Samor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chtourou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,3,15]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood.V72.5.1449.1449","article-title":"Desmopressin: a non\u2010transfusional form of treatment for congenital and acquired bleeding disorders","volume":"72","author":"Mannucci PM","year":"1988","journal-title":"Blood"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1992.tb01159.x"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1991.tb00918.x"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x"},{"key":"e_1_2_4_6_2","first-page":"CPMP\/269\/95","volume-title":"Note for Guidance on Plasma\u2010Derived Medicinal Products.","author":"The European Agency for the Evaluation of Medicinal Products:","year":"1997"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(76)90527-3"},{"key":"e_1_2_4_8_2","first-page":"18","article-title":"Dosage de l\u2019antig\u00e8ne li\u00e9 au facteur VIII par la technique ELISA. Int\u00e9r\u00eat dans l\u2019\u00e9tude de la maladie de Willebrand","volume":"25","author":"Mazurier C","year":"1977","journal-title":"Pathol Biol (Paris) Suppl."},{"key":"e_1_2_4_9_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0038-1661448","article-title":"Improved characterization of plasma von Willebrand factor heterogeneity when using 2\u00b75% agarose gel electrophoresis","volume":"55","author":"Mazurier C","year":"1986","journal-title":"Thromb Haemost"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1989.tb01244.x"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111228"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1987.tb02981.x"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(86)90150-7"},{"key":"e_1_2_4_14_2","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood.V95.10.3139","article-title":"Conformational changes in the D\u2032 domain of von Willebrand factor induced by Cys25 and Cys95 mutations lead to factor VIII binding defect and multimeric impairment","volume":"95","author":"Jorieux S","year":"2000","journal-title":"Blood"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613027"},{"key":"e_1_2_4_16_2","unstructured":"WalterO BuddeU MetznerHJ MuysersC SuiterTM: Dependence of von Willebrand factor activity in relation to the high\u2010molecular\u2010weight von Willebrand factor multimers in various FVIII\/VWF concentrates. Abstract 3883 at the 44th annual meeting of theAmerican Society of Hematology Philadelphia December 2002"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0042-9007.2004.00398.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0042-9007.2004.00398.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T20:29:36Z","timestamp":1696883376000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0042-9007.2004.00398.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1111\/j.0042-9007.2004.00398.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0042-9007.2004.00398.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}